Highlights

  • EBR Systems (ASX:EBR) generated US$5.0 million in net sales for the six months ended 30 June 2026 as commercial adoption of its WiSE System expanded in the United States.
  • Commercial implants were completed at 29 US hospitals during the first half of 2026, compared with three hospitals in the corresponding period.
  • Cash, cash equivalents and marketable securities totalled approximately US$86.9 million at 30 June 2026, following a Capital raising completed during June.
  • At the time of writing this article, EBR Systems (ASX:EBR) was trading at AUD 0.26, up 4.00% during today’s trading session.

At the time of writing this article, EBR Systems (ASX:EBR) was trading at AUD 0.26, up 4.00% during today’s trading session. EBR Systems is a medical technology company developing wireless cardiac pacing technology for patients requiring cardiac resynchronisation therapy. Its principal product is the WiSE System, a leadless left ventricular endocardial pacing system designed to provide cardiac stimulation without a conventional left ventricular pacing lead. During 2026, the company has focused on expanding US commercial adoption, increasing hospital participation, supporting post-approval clinical activity and building its financial resources for commercial operations.

Company Business

EBR Systems is headquartered in California and develops the Wireless Stimulation Endocardially, or WiSE, technology platform. The system delivers left ventricular pacing using ultrasound energy transferred from an implanted transmitter to a small electrode positioned inside the left ventricle. The electrode converts the ultrasound energy into an electrical pacing pulse.

The WiSE System is designed for patients requiring cardiac resynchronisation therapy where conventional approaches may not be suitable or have not delivered the intended result. The system works with existing cardiac pacing devices, allowing left ventricular endocardial pacing without a coronary sinus lead. EBR’s commercial activities are currently concentrated predominantly in the United States.

Recent Development

During 2026, EBR continued expanding commercial use of the WiSE System across US hospitals. For the three months ended 30 June 2026, the company completed commercial implants at 23 US hospitals. Across the first six months of the year, commercial implants were completed at 29 hospitals.

In September 2026, the company also highlighted the first use of the WiSE System in an adult patient with congenital heart disease. The procedure was undertaken at Northwell Health in New York, adding another clinical use case to the company’s growing commercial experience.

EBR is also progressing the WiSE-UP post-approval study, which is intended to gather real-world performance information from patients treated with the commercial WiSE System. The company’s ongoing clinical expenditure during 2026 includes costs associated with this post-approval program.

Financial Performance and Sector Context

For the six months ended 30 June 2026, EBR reported net sales of US$5.0 million, including approximately US$4.996 million generated in the United States. This compared with US$0.17 million in net sales in the corresponding period. Gross Profit was US$0.527 million, while gross Margin was 10.5%.

The company reported a net loss of US$34.5 million for the first half of 2026, compared with a US$22.5 million loss in the corresponding period. Research and Development expenditure increased 14.7% to approximately US$13.0 million, reflecting higher clinical expenditure, quality assurance costs and facility-related expenses.

At 30 June 2026, EBR held approximately US$59.4 million in cash and cash equivalents and US$26.6 million in marketable securities, taking combined Liquidity to approximately US$86.9 million. The company also reported negative Operating Cash Flow of US$37.4 million for the six-month period.

During June, EBR undertook an approximately A$150 million fully underwritten Equity raising comprising placements and a pro-rata entitlement offer. The company subsequently stated that the raising contributed to the increase in Working Capital recorded at the end of June.

The cardiac device sector is influenced by hospital adoption, physician training, reimbursement arrangements, regulatory compliance and Manufacturing capacity. These factors remain relevant as EBR transitions from development toward broader commercial use.

Risks to Consider

EBR remains exposed to commercial execution risk as it expands the WiSE System across additional treatment centres. Hospital adoption depends on physician training, procedural integration, reimbursement and clinical use.

Financial considerations also remain relevant. EBR continues to incur operating losses and negative operating cash flow while expanding commercial operations. Manufacturing scale-up, post-approval study requirements, regulatory compliance and product reliability are additional factors that may affect the company’s operating profile.

What to Watch Next

Key areas to monitor include growth in the number of hospitals performing commercial WiSE procedures, patient volumes and corresponding sales.

Further progress in the WiSE-UP post-approval study will provide additional real-world evidence on system performance. EBR’s manufacturing expansion is another monitoring point as the company develops its facilities to support increasing commercial requirements.

Future financial reports will also provide information on Revenue development, gross margin, operating expenditure and the use of proceeds from the 2026 capital raising.

Key Insights

EBR Systems is progressing through the commercialisation phase of the WiSE System, with first-half 2026 results showing increased sales and wider US hospital adoption. Net sales reached approximately US$5.0 million during the six months ended June, while commercial procedures were undertaken across 29 US hospitals.

The company also expanded its liquidity position following the June capital raising, although operating losses and cash expenditure remain material as commercial, manufacturing and post-approval activities continue. Future developments will centre on hospital adoption, procedure volumes, revenue growth, clinical follow-up and management of the company’s funding position.